MANOJKUMAR BUPATHI
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology LITTLETON, CO NPI 1265675433
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology CO EISAI INC. All categories
General Payments — all program years on this page
$338,781.01
- Category: General Payments
- Program years: PY2018–2024
- Record count: 352
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $60,929.56 across 77 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $34,744.50 | 14 |
| Travel and Lodging | $9,055.12 | 10 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,884.00 | 4 |
| Honoraria | $6,377.50 | 4 |
| Food and Beverage | $1,543.46 | 41 |
| Education | $324.98 | 4 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| EISAI INC. | $13,149.66 | 11 |
| EMD Serono, Inc. | $11,628.93 | 4 |
| PFIZER INC. | $8,967.82 | 10 |
| Merck Sharp & Dohme Corporation | $6,259.13 | 6 |
| Astellas Pharma US Inc | $6,110.90 | 8 |
| Bayer HealthCare Pharmaceuticals Inc. | $5,101.00 | 3 |
| Acerta Pharma LLC | $3,792.50 | 3 |
| Exelixis Inc. | $2,776.78 | 4 |
| AVEO Pharmaceuticals, Inc. | $1,694.84 | 4 |
| Janssen Scientific Affairs, LLC | $817.50 | 1 |
| Janssen Biotech, Inc. | $164.90 | 4 |
| Gilead Sciences, Inc. | $139.82 | 7 |
| TerSera Therapeutics LLC | $86.07 | 3 |
| ABBVIE INC. | $80.99 | 4 |
| Celgene Corporation | $77.53 | 1 |
| E.R. Squibb & Sons, L.L.C. | $30.18 | 1 |
| TOLMAR, INC. | $19.99 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $16.40 | 1 |
| Ferring Pharmaceuticals Inc. | $14.62 | 1 |
By program year
Records — PY2024 (77)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.